Keywords: اومالیزوماب; Anti-IgE antibody; Management; Omalizumab; Retreatment; Urticaria; ANA; anti-nuclear antibody; CMS; concomitant medication score; CRP; C-reactive protein; CSU; chronic spontaneous urticaria; ESR; erythroid sedimentation rate; Tg; thyroglobulin; TPO; thyro
مقالات ISI اومالیزوماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: اومالیزوماب; Urticaria; Guidelines; Antihistamines; Omalizumab; Cyclosporine; anti-H1; H1 antihistamines; CSU; Chronic spontaneous urticaria; DLQI; Dermatology Life Quality Index; EAACI; European Academy of Allergy and Clinical Immunology; UAS; Urticaria Activity Scor
Keywords: اومالیزوماب; Adverse drug events; Effectiveness; Exacerbations; Omalizumab; Severe asthma; ADRs; adverse drug reaction; AEs; adverse events; GETE; global evaluation of treatment effectiveness; GINA; Global Initiative for Asthma; HCRU; health care resource utilization;
Keywords: اومالیزوماب; Omalizumab; Severe asthma; Real-life; Therapeutic response; Age; Obesity; Comorbidities;
Keywords: اومالیزوماب; Urticaria; Biomarkers; CRP; IL-6; MPV; D-dimer; F1+2; Biologics; Omalizumab; ASCENT-I; ASCENT-II; GLACIAL; IL-1 antagonists; TNF-α inhibitors; Intravenous immunoglobulin; Rituximab; Ligelizumab; Quilizumab; ASST; Autologous serum skin test; ATA; Antithyr
Keywords: اومالیزوماب; Food allergy; Adjuvants; Probiotics; Bacterial adjuvants; Omalizumab; Interferon gamma;
Keywords: اومالیزوماب; Asthma; Omalizumab; Medication adherence; Asthma exacerbation; Asthma control; CIU; Chronic idiopathic urticaria; COPD; Chronic obstructive pulmonary disease; ED; Emergency department; EXCELS; Evaluating Clinical Effectiveness and Long-term Safety in Pati
Keywords: اومالیزوماب; acute; antihistamines; children; chronic; corticosteroids; elderly; leukotriene receptor antagonists; management; omalizumab; quality of life; urticaria; ASST; autologous serum skin test; AU; acute urticaria; BB-UVB; broadband ultraviolet B; CSU; chronic
Keywords: اومالیزوماب; Light; Omalizumab; Photoprovocation; Solar urticaria; BID; Twice daily; CSU; Chronic spontaneous urticaria; MUD; Minimal urticaria dose; QD; Once daily; SU; Solar urticaria; UVA; Ultraviolet A; UVB; Ultraviolet B; VL; Visible light;
Keywords: اومالیزوماب; Plasmacytoid dendritic cells; rhinovirus; IFN-α; asthma; IgE; omalizumab; FcεRα; IRF; Interferon regulatory factor; pDC; Plasmacytoid dendritic cell; PROSE; Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations; RIG-I; Retinoic acid-induc
Keywords: اومالیزوماب; Omalizumab; Severe asthma; Treatment duration; Real-life; Response; Effectiveness;
Keywords: اومالیزوماب; Calidad de vida; Urticaria crónica espontánea; Omalizumab; Cuestionario calidad de vida; Quality of life; Chronic spontaneous urticaria; Omalizumab; Quality of life questionnaire;
Keywords: اومالیزوماب; Asthma; IgE; Omalizumab; Allergy; Exacerbations;
Keywords: اومالیزوماب; Mepolizumab; Omalizumab; Severe asthma; Exacerbations; Lung function; Tolerability; Crl; credible interval; HRQoL; health related quality of life; ITC; indirect treatment comparison; MEPO; mepolizumab; OCS; oral corticosteroid; OMA; omalizumab; RCT; rando
Keywords: اومالیزوماب; Urticaria crónica inducible; Omalizumab; Urticaria por frÃo; Urticaria solar; Urticaria por presión retardada; Urticaria colinérgica; Urticaria por calor; Chronic inducible urticaria; Omalizumab; Cold urticaria; Solar urticaria; Delayed pressure urtic
Keywords: اومالیزوماب; Childhood asthma; Efficacy; Omalizumab; Safety evaluation; Total IgE; AEs; adverse events; ER; emergency room; EOT; end of the treatment period; ELISA; enzyme-linked immunosorbent assay; FP; fluticasone propionate; FEV1; forced expiratory volume in 1Â s;
Keywords: اومالیزوماب; Allergy bronchopulmonary aspergillosis; Aspergillus fumigates; exacerbation; Omalizumab; Prednisone dosage; ABPA; Allergy bronchopulmonary aspergillosis; IgE; Immunoglobulin E; mAb; monoclonal Ab; TB; Tuberculosis; CF; Cystic Fibrosis; FeNO; Fractional Co
Keywords: اومالیزوماب; Urticaria; Angio-oedema; Consensus; Delphi; Delphi technique; Omalizumab;
Keywords: اومالیزوماب; Drug development; Drug delivery; Adherence; Inhaled corticosteroids; Long-acting β-agonists; Tiotropium; Biologics; Omalizumab;
Keywords: اومالیزوماب; Omalizumab; Allergic asthma; IgE; Meta-analysis; Effectiveness; ACT; Asthma Control Test; AQLQ; Asthma-related Quality-of-Life Questionnaire; FEV1; Forced expiratory volume in 1 second; GETE; Global Evaluation of Treatment Effectiveness scale; ICS; Inhale
Keywords: اومالیزوماب; Adalimumab; Etanercept; Omalizumab; Insulin; Injection site reactions; Systemic hypersensitivity reactions; MoAbs; TNF-α inhibitors;
Keywords: اومالیزوماب; Guide; Oral immunotherapy; Desensitization; Specific oral tolerance induction; Milk allergy; Egg allergy; Omalizumab; Sublingual immunotherapy;
Keywords: اومالیزوماب; Fall asthma exacerbation; omalizumab; guidelines-based therapy; asthma exacerbation predictors; Seasonal Asthma Exacerbation Predictive Index (saEPI); AUC; Area under the curve; FENO; Fractional exhaled nitric oxide; GBT; Guidelines-based therapy; ICAC; I
Keywords: اومالیزوماب; Urticaria; Angioedema; Psoriasis; Atopic dermatitis; Biologic agents; Omalizumab; Dupilimab;
Keywords: اومالیزوماب; Allergy; asthma; IgE; omalizumab; pediatric; AA; Allergic asthma; AE; Adverse event; EMA; European Medicines Agency; EXCELS; Epidemiologic Study of Xolair (omalizumab): Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-Se
Keywords: اومالیزوماب; Biologic agents; Monoclonal antibodies; Infusion reaction; Delayed reaction; Drug desensitization; Omalizumab; Rituximab;
Keywords: اومالیزوماب; Chronic urticaria; Biologics; Omalizumab; Therapy; Rituximab; TNF antagonist; Intravenous immunoglobulin therapy;
Keywords: اومالیزوماب; Cystic fibrosis; Allergic bronchopulmonary aspergillosis; Omalizumab; Lung function;
Keywords: اومالیزوماب; Oral immunotherapy; food allergy; milk allergy; omalizumab; desensitization; sustained unresponsiveness; basophil activation; biomarker; regulatory T cells; AUC; Area under the curve; FoxP3; Forkhead box P3; HR; Histamine release; MOIT; Milk oral immunoth
Keywords: اومالیزوماب; Peanut allergy; food allergy; desensitization; omalizumab; DBPCFC; Double-blind, placebo-controlled food challenge; EoE; Eosinophilic esophagitis; ITT; Intention to treat; OIT; Oral immunotherapy; SPT; Skin prick test;
Keywords: اومالیزوماب; Bronchial thermoplasty; difficult-to-control asthma; exacerbations; mepolizumab; omalizumab; phenotypes; severe asthma
Keywords: اومالیزوماب; Asma grave no controlada; Omalizumab; Costes; Administración ambulatoria; Uncontrolled severe asthma; Omalizumab; Costs; Ambulatory administration;
Keywords: اومالیزوماب; Uncontrolled severe asthma; Omalizumab; Costs; Ambulatory administrationAsma grave no controlada; Omalizumab; Costes; Administración ambulatoria
Keywords: اومالیزوماب; Asthma; Omalizumab; Therapeutic program; Real-life study; astma; omalizumab; program terapeutyczny; badanie w warunkach rzeczywistych;
Keywords: اومالیزوماب; Omalizumab; chronic idiopathic urticaria; chronic spontaneous urticaria; responder analysis; complete response; well-controlled urticaria; CIU; Chronic idiopathic urticaria; CSU; Chronic spontaneous urticaria; LTRA; Leukotriene receptor antagonist; UAS; U
Keywords: اومالیزوماب; Airway hyperresponsiveness; airway inflammation; asthma; inhaled corticosteroids; methacholine challenge; omalizumab
Keywords: اومالیزوماب; Food allergy; Oral immunotherapy (OIT); Desensitization; Tolerance; Sustained unresponsiveness; Skin prick test (SPT); Immunoglobulin E (IgE); Omalizumab;
Keywords: اومالیزوماب; Asthma; childhood asthma; dupilumab; inhaled corticosteroids; lebrikizumab; nitric oxide; mepolizumab; omalizumab; severe asthma;
Keywords: اومالیزوماب; Peanut allergy; food allergy; omalizumab; IgE; gene therapy; mouse model; AAV; Adeno-associated virus; GVHD; Graft-versus-host disease; hIgE; Human IgE; NSG; NOD-scid IL2Rgammanull; PCA; Passive cutaneous anaphylaxis;
Keywords: اومالیزوماب; Asthma; Early asthma; Inhaled corticosteroids; Lebrikizumab; Mepolizumab; Omalizumab; Severe asthma; Tiotropium;
Keywords: اومالیزوماب; Severe asthma; Omalizumab; Asthma control; Exacerbations; Observational study
Keywords: اومالیزوماب; Asthma; Omalizumab; Control; Exacerbations; Comorbidities; Exhaled nitric oxide;
Keywords: اومالیزوماب; Severe asthma; Omalizumab; Biological; Anti-IgE; Difficult-to-control asthma; Hospitalisation; Emergency room; Asthmatic crisis; Asthma exacerbation
Keywords: اومالیزوماب; Bronchial asthma; Children; Japanese; Omalizumab; Quality of lifeAE, Adverse event; ELISA, Enzyme-linked immunosorbent assay; ER, Emergency room; FEF25–75%, Forced expiratory flow rate at 25%–75% of forced vital capacity; FEV1, Forced expiratory volume in
Keywords: اومالیزوماب; Chronic urticaria; omalizumab; IgE; FcεRI; autoantibodies; mast cells; activation/release threshold; IgE-FcεRI-mast cell axis; ASST; Autologous serum skin test; CSU; Chronic spontaneous urticaria; CU; Chronic urticaria; dsDNA; Double-stranded DNA; H
Keywords: اومالیزوماب; Omalizumab; Severe allergic asthma; Comorbidities; Efficacy; Effectiveness; Safety;
Keywords: اومالیزوماب; Omalizumab; Urticaria; Chronic spontaneous; Chronic idiopathic; Itch; Hive; Pruritus; Wheal; Antihistamine; AE; Adverse event; CI; Confidence interval; CIU; Chronic idiopathic urticaria; CSU; Chronic spontaneous urticaria; CU; Chronic urticaria; DLQI; Der
Keywords: اومالیزوماب; Asthma; asthma control; asthma exacerbations; dupilumab; biomarkers; inhaled corticosteroids; lebrikizumab; long-acting Ã-adrenergic agonists; mepolizumab; omalizumab; reslizumab; severe asthma; therapeutics; ACQ; Asthma control questionnaire; BADGER; Be
Keywords: اومالیزوماب; Asthma; Asthma management; Pediatric asthma; Biologics; Omalizumab;
Keywords: اومالیزوماب; Food allergy/hypersensitivity; Anaphylaxis; Food allergy treatment; Immunotherapy; Desensitization; Tolerance; Probiotics; Omalizumab;